Efficacy and safety of sacubitril/valsartan on heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials
AimsThe efficacy and safety of sacubitril/valsartan for patients with heart failure with preserved ejection fraction (HFpEF) are controversial. Hence, the primary objective of the study was to evaluate the efficacy and safety of sacubitril/valsartan treatment for patients with HFpEF.Methods and resu...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2022.897423/full |
| _version_ | 1798002137773375488 |
|---|---|
| author | Wanqian Yu Hongzhou Zhang Wen Shen Fan Luo Shuai Yang Lujin Gan Yuanbin Zhao Pingping Yang Qinghua Wu |
| author_facet | Wanqian Yu Hongzhou Zhang Wen Shen Fan Luo Shuai Yang Lujin Gan Yuanbin Zhao Pingping Yang Qinghua Wu |
| author_sort | Wanqian Yu |
| collection | DOAJ |
| description | AimsThe efficacy and safety of sacubitril/valsartan for patients with heart failure with preserved ejection fraction (HFpEF) are controversial. Hence, the primary objective of the study was to evaluate the efficacy and safety of sacubitril/valsartan treatment for patients with HFpEF.Methods and resultsWe used the PubMed, Embase, and Web of Science databases to search for randomized controlled trials of sacubitril–valsartan in patients with HFpEF. Three studies, involving a total of 7,663 patients, were eligible for inclusion. Sacubitril–valsartan reduced the risk of hospitalization for heart failure (HF) [odds ratio (OR): 0.78; 95% CI: 0.70–0.88; p < 0.0001] and the incidence of worsening renal function [risk ratio (RR): 0.79, p = 0.002] among patients with HFpEF in the three trials, but there was no significant reduction in all-cause mortality (0.99, 95% CI: 0.84–1.15; p = 0.86) or cardiovascular mortality (0.95, 95% CI: 0.78–1.15; p = 0.16). Moreover, sacubitril/valsartan was associated with an increased risk of symptomatic hypotension (RR: 1.44; p < 0.00001) and angioedema (RR: 2.66; p < 0.04); there was no difference for decreasing the incidence of hyperkalemia (RR: 0.89; p = 0.11).ConclusionCompared with valsartan or individualized medical therapy (IMT), sacubitril/valsartan significantly decreased the risk of hospitalization for HF and reduced the incidence of renal dysfunction. |
| first_indexed | 2024-04-11T11:47:23Z |
| format | Article |
| id | doaj.art-2ebac6005d084d4d98def1392fc8ef2d |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-04-11T11:47:23Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-2ebac6005d084d4d98def1392fc8ef2d2022-12-22T04:25:30ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2022-09-01910.3389/fcvm.2022.897423897423Efficacy and safety of sacubitril/valsartan on heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trialsWanqian Yu0Hongzhou Zhang1Wen Shen2Fan Luo3Shuai Yang4Lujin Gan5Yuanbin Zhao6Pingping Yang7Qinghua Wu8Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaDepartment of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaDepartment of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaMedical Center of the Graduate School, Nanchang University, Nanchang, ChinaDepartment of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaDepartment of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaDepartment of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaDepartment of Endocrinology and Metabolism, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaDepartment of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, ChinaAimsThe efficacy and safety of sacubitril/valsartan for patients with heart failure with preserved ejection fraction (HFpEF) are controversial. Hence, the primary objective of the study was to evaluate the efficacy and safety of sacubitril/valsartan treatment for patients with HFpEF.Methods and resultsWe used the PubMed, Embase, and Web of Science databases to search for randomized controlled trials of sacubitril–valsartan in patients with HFpEF. Three studies, involving a total of 7,663 patients, were eligible for inclusion. Sacubitril–valsartan reduced the risk of hospitalization for heart failure (HF) [odds ratio (OR): 0.78; 95% CI: 0.70–0.88; p < 0.0001] and the incidence of worsening renal function [risk ratio (RR): 0.79, p = 0.002] among patients with HFpEF in the three trials, but there was no significant reduction in all-cause mortality (0.99, 95% CI: 0.84–1.15; p = 0.86) or cardiovascular mortality (0.95, 95% CI: 0.78–1.15; p = 0.16). Moreover, sacubitril/valsartan was associated with an increased risk of symptomatic hypotension (RR: 1.44; p < 0.00001) and angioedema (RR: 2.66; p < 0.04); there was no difference for decreasing the incidence of hyperkalemia (RR: 0.89; p = 0.11).ConclusionCompared with valsartan or individualized medical therapy (IMT), sacubitril/valsartan significantly decreased the risk of hospitalization for HF and reduced the incidence of renal dysfunction.https://www.frontiersin.org/articles/10.3389/fcvm.2022.897423/fullsacubitril/valsartanLCZ696heart failureheart failure with preserved ejection fraction (HFpEF)meta-analysis |
| spellingShingle | Wanqian Yu Hongzhou Zhang Wen Shen Fan Luo Shuai Yang Lujin Gan Yuanbin Zhao Pingping Yang Qinghua Wu Efficacy and safety of sacubitril/valsartan on heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials Frontiers in Cardiovascular Medicine sacubitril/valsartan LCZ696 heart failure heart failure with preserved ejection fraction (HFpEF) meta-analysis |
| title | Efficacy and safety of sacubitril/valsartan on heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials |
| title_full | Efficacy and safety of sacubitril/valsartan on heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials |
| title_fullStr | Efficacy and safety of sacubitril/valsartan on heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials |
| title_full_unstemmed | Efficacy and safety of sacubitril/valsartan on heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials |
| title_short | Efficacy and safety of sacubitril/valsartan on heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials |
| title_sort | efficacy and safety of sacubitril valsartan on heart failure with preserved ejection fraction a meta analysis of randomized controlled trials |
| topic | sacubitril/valsartan LCZ696 heart failure heart failure with preserved ejection fraction (HFpEF) meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2022.897423/full |
| work_keys_str_mv | AT wanqianyu efficacyandsafetyofsacubitrilvalsartanonheartfailurewithpreservedejectionfractionametaanalysisofrandomizedcontrolledtrials AT hongzhouzhang efficacyandsafetyofsacubitrilvalsartanonheartfailurewithpreservedejectionfractionametaanalysisofrandomizedcontrolledtrials AT wenshen efficacyandsafetyofsacubitrilvalsartanonheartfailurewithpreservedejectionfractionametaanalysisofrandomizedcontrolledtrials AT fanluo efficacyandsafetyofsacubitrilvalsartanonheartfailurewithpreservedejectionfractionametaanalysisofrandomizedcontrolledtrials AT shuaiyang efficacyandsafetyofsacubitrilvalsartanonheartfailurewithpreservedejectionfractionametaanalysisofrandomizedcontrolledtrials AT lujingan efficacyandsafetyofsacubitrilvalsartanonheartfailurewithpreservedejectionfractionametaanalysisofrandomizedcontrolledtrials AT yuanbinzhao efficacyandsafetyofsacubitrilvalsartanonheartfailurewithpreservedejectionfractionametaanalysisofrandomizedcontrolledtrials AT pingpingyang efficacyandsafetyofsacubitrilvalsartanonheartfailurewithpreservedejectionfractionametaanalysisofrandomizedcontrolledtrials AT qinghuawu efficacyandsafetyofsacubitrilvalsartanonheartfailurewithpreservedejectionfractionametaanalysisofrandomizedcontrolledtrials |